Compare abrdn Income Credit Strategies Fund (ACP) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
abrdn Income Credit Strategies Fund vs Johnson & Johnson — how do they compare? abrdn Income Credit Strategies Fund trades at $5.15 (market cap $641.16M), while Johnson & Johnson trades at $260.53 (market cap $626.09B). The key difference: Johnson & Johnson is far larger — about 976.5× abrdn Income Credit Strategies Fund's market cap, and abrdn Income Credit Strategies Fund pays the higher dividend (18.2%). Which is the better fit depends on your goals.
| ACP | JNJ | |
|---|---|---|
Market Cap | $641.16M | $626.09B |
Sector | Financials | Health |
52-Week High | $5.98 | $267.24 |
52-Week Low | $5.01 | $172.78 |
Dividend Yield | 18.2% | 2.06% |
Volume | — | 6,156,228 |
Enterprise Value | — | $654.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACP trades at $5.14, up 1.18% today, with a neutral technical signal and bearish moving averages. The stock shows strong profitability with a net income margin of 95.31% and a low P/E of 7.74, though revenue declined to $42.46M in 2025 from $79M in 2024. Recent news highlights dividend declarations and a Seeking Alpha downgrade citing distribution sustainability concerns.
The outlook is mixed: attractive valuation and high dividends offer income appeal, but revenue volatility and high leverage pose risks. Analyst sentiment is cautious due to unsustainable distribution rates and tight credit spreads, requiring careful monitoring of earnings and credit conditions for future performance.
Johnson & Johnson (JNJ) trades at $261.26, down 0.21% on the day, near its 52-week high. The stock shows a bullish technical trend with strong moving averages and recent earnings beats. Revenue grew to $94.19B in 2025, with a net income margin of 21.48%, though cash flow turned negative due to heavy investing. The company maintains a robust dividend history, with consistent payouts and a 64-year growth streak.
Outlook remains positive with a consensus price target of $284.50, offering ~9% upside. Risks include legal headwinds and patent expirations, but analyst sentiment is bullish (52.5% buy ratings). JNJ's defensive profile and pipeline strength support long-term growth, though investors should monitor debt levels, which rose to 24.06% of assets in 2025.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About abrdn Income Credit Strategies Fund
abrdn Income Credit Strategies Fund is a diversified, closed-end investment management company. Its primary goal is to generate high current income, with capital appreciation as a secondary objective. The fund mainly invests in debt and loan instruments from issuers across various industries and regions.
Read more on ACP →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
